<DOC>
	<DOCNO>NCT01982539</DOCNO>
	<brief_summary>As part PREA ( Pediatric Research Equity Act ) commitment , objective study confirm safety tolerability 25 mg Zipsor® clinical pediatric subject .</brief_summary>
	<brief_title>Safety Tolerability Zipsor® Pediatric Subjects ( Ages 12-17 Years ) With Mild Moderate Acute</brief_title>
	<detailed_description>Open-label study , subject dose Zipsor® treatment mild moderate acute pain 4 day .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Male female subject 1217 year age . Subjects must postop , mild moderate acute pain . Other inclusion apply . Subject known history allergic reaction , hypersensitivity diclofenac , aspirin , acetaminophen , reaction nonactive ingredient study medication . Subject take analgesic 4872 hour prior Screening . Subject history GI event great 6 month Screening . Subject currently receive medication contraindicate use concomitantly diclofenac acetaminophen . Subject previously participate another clinical study Zipsor take Zipsor indication . Subject require treatment preexist hypertension . Other exclusion apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>pain</keyword>
	<keyword>NSAID</keyword>
	<keyword>moderate pain</keyword>
	<keyword>mild pain</keyword>
	<keyword>acute pain</keyword>
	<keyword>mild acute pain</keyword>
	<keyword>moderate acute pain</keyword>
	<keyword>mild moderate acute pain</keyword>
</DOC>